Genprex (NASDAQ:GNPX) Stock Price Down 0.4% – Here’s What Happened

Genprex (NASDAQ:GNPX) shares fell 0.4% on Monday. The company traded as low as $2.16 and last traded at $2.23. 241,574 shares changed hands during mid-day trading, an increase of 27% from the average session volume of 190,479 shares. The stock had previously closed at $2.24.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has an average rating of “Sell”.

Genprex Price Performance

The firm has a 50-day moving average price of $2.86 and a two-hundred day moving average price of $19.89.

Genprex (NASDAQ:GNPX) last posted its quarterly earnings results on Friday, August 14th. The company reported ($9.40) earnings per share for the quarter.

Genprex Company Profile

Genprex, Inc is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s approach is based on delivering therapeutic genes to diseased cells using non-viral delivery systems, including lipid nanoparticles.

Genprex’s lead program, REQORSA Immunogene Therapy, is designed to deliver the TUSC2 tumor-suppressor gene to cancer cells. The company has been evaluating REQORSA in combination with established treatments for non-small cell lung cancer, including targeted and immune-based therapies.